Advent to take majority stake in NZ clinical research
MASSACHUSETTS, UNITED STATES — Advent International agreed to acquire a majority stake in New Zealand Clinical Research Group (NZCR Group) from Waterman Capital and clinician shareholders.
New Zealand media reported the transaction at approximately NZ$1 billion (approximately US$600 million); Advent did not disclose official deal terms. Waterman Capital and NZCR Group’s clinician shareholders will retain a significant minority stake following closing.
Advent targets pharma sponsor depth and global reach
According to a report from Lawrence Evans, Advent International said its acquisition of NZCR Group will deepen sponsor relationships and extend NZCR’s network into new international markets through Advent’s global pharmaceutical services portfolio.
NZCR Group operates Phase I through Phase IV clinical trials under four brands (NZCR, CMAX, Optimal, and Fusion) across New Zealand and Australia, making it one of the region’s most comprehensive knowledge process outsourcing (KPO) platforms for physician-led clinical research in early and late-phase studies.
The transaction is expected to close in the fourth quarter of 2026, subject to regulatory approvals.
“We look forward to partnering with management and existing shareholders to unlock NZCR Group’s full potential and introduce the business into Advent’s global network,” said Beau Dixon, managing director and head of Australia and New Zealand at Advent International.
Existing shareholders retain meaningful minority stake
Waterman Capital, which previously held a 52% stake, and NZCR Group’s clinician shareholders will remain as equity partners in the combined entity, preserving the physician-led ownership model that has defined NZCR Group’s positioning with pharmaceutical sponsors.
Advent’s acquisition extends a period of private equity consolidation in the clinical trials outsourcing sector, where CRO networks carrying established Phase I track records and strong sponsor relationships are attracting global capital at premium valuations.
NZCR Group brings 35 years of clinical research experience and a broad patient population base across New Zealand and Australia.
“Advent’s global scale and deep experience in pharma services will help us grow in ways that weren’t possible before, connecting us to new markets, sponsors, and opportunities,” said Tony Moffatt, group chief executive of NZCR Group.
Advent’s move into the New Zealand and Australian clinical trials market reflects growing global private equity interest in physician-led contract research organizations operating in high-trust, regulation-mature markets with established pharmaceutical sponsor relationships.
For the healthcare outsourcing sector, the NZCR acquisition illustrates how regional CRO platforms with end-to-end Phase I through Phase IV capability are attracting capital and acquiring global reach through PE-backed international integration.
With Advent’s network behind it, NZCR Group is positioned to expand its sponsor relationships and Asia-Pacific footprint in ways that its prior ownership structure, anchored to a New Zealand and Australia base, could not fully support.
Related news
- Knox Lane acquires Cross Country Healthcare · 21 Jul
- Health Catalyst completes Vitalware sale · 12 Aug
- CRC Advisors buys BBKS & Co · 8 Aug
Disclosure: Outsource Accelerator uses AI tools in the backend of its editorial workflow. Every article is reviewed and verified by a human editor before publication.
Stay ahead of the outsourcing industry. Join thousands of business leaders who rely on Outsource Accelerator for the news, trends, and expert insights that matter. Subscribe to our free newsletter and never miss an update.
